Cancer Research UK has announced that it has initiated a clinical trial that will allow patients taking part to stay at home and take the medication in tablet form.
Clinical trials are vital in the development of new cancer treatment, but are often hindered by the commitment issues, as patients usually need to stay in hospitals for long periods of time.
"It's great news that we're able to run a trial of this exciting drug as a tablet which will be a much more convenient and comfortable way to receive the treatment," said professor Ruth Plummer, the trial's chief investigator.
She explained that making the drug available in tablet form allowed participants to regain some semblance of normality, as they would not be hooked up to a drip.
Patients will test the effectiveness of Rucaparib, a PARP inhibitor, which has so far displayed promising results when used to treat breast cancer.
Scientists funded by the charity recently discovered that oestrogen concentrations are linked to the likelihood of a breast cancer relapse.